10x Genomics, Inc. (TXG)

10x Genomics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-264.3	-255.1	-166	-58.22	-542.73	-31.25
Depreciation & Amortization	46.5	43.62	33.01	28.25	19.02	7.07
Share-Based Compensation	160.98	166.95	136.85	95.96	48.63	13.33
Other Operating Activities	30.03	29.33	-37.46	-87.37	257.19	45.48
Operating Cash Flow	-26.8	-15.2	-33.61	-21.37	-217.9	34.63
Capital Expenditures	-46.95	-48.6	-131.66	-101.28	-36.67	-42.74
Acquisitions	0	0	-4	-5.45	0	0
Change in Investments	71.32	183.02	-215.23	0	0	0
Other Investing Activities	-0.2	-0.92	-	-	-1.73	-0.03
Investing Cash Flow	24.17	133.49	-350.89	-106.73	-38.39	-42.77
Share Issuance / Repurchase	18.72	19.48	21.23	40.33	506.01	414.59
Debt Issued / Paid	5.81	0	0	0	-31.26	0
Other Financing Activities	-5.81	-5.81	-5.41	-5.03	-5.85	-
Financing Cash Flow	18.72	13.67	15.82	35.3	468.91	414.59
Exchange Rate Effect	-0.11	-0.03	-0.04	0.23	-0.46	-0.05
Net Cash Flow	15.99	131.93	-368.72	-92.57	212.15	406.41
Free Cash Flow	-73.75	-63.8	-165.27	-122.65	-254.56	-8.12
Free Cash Flow Margin	-11.79%	-10.31%	-32.00%	-25.01%	-85.18%	-3.30%
Free Cash Flow Per Share	-0.62	-0.55	-1.45	-1.11	-2.52	-0.21

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).